Clinical trials: Partial Epilepsy
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Epilepsies, Partial
A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure
The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy…
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00230698
- Testing
- topiramate
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource…
- Trial name
- NCT01728077
- Testing
- Brivaracetam
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 26 people
- Sponsor
- UCB Pharma SA
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
This is a Phase III, multinational, open-label, non-controlled study with subjects under treatment in the double-blind BIA-2093-311 study (NCT01162460).
- Trial name
- NCT02484001
- Testing
- ESL 800 mg, ESL 1200 mg, ESL 1600 mg
- Volunteers
- 206 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial…
- Trial name
- NCT00105040
- Testing
- Levetiracetam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- UCB Pharma
Epilepsy; Seizure, Focal Epilepsy
Seizures Detection in Real Life Setting
Epilepsy is a disabling neurological disease that affects tens of millions of people worldwide. Despite therapeutic advances, about a third of these patients suffer from treatment-resistant forms of epilepsy and still experience…
- Trial name
- ECEME (NCT05635396)
- Testing
- Wearable, non invasive sensor for seizure detection
- Volunteers
- 12 people
- Sponsor
- Reliev Technologies
Partial Seizures
Pregabalin Epilepsy Add-On Trial
To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures
- Trial name
- NCT00141258
- Testing
- pregabalin
- Where
- 5 sites in South Korea
- Volunteers
- 178 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.